Skip to main content
. 2020 Sep 1;20:829. doi: 10.1186/s12885-020-07329-8

Table 7.

Probabilistic sensitivity analysis results according to PFS and OS. Amounts are presented in MXN pesos

TKI Mean total cost Incremental Cost Effectiveness Incremental Effectiveness ICER
Progression Free Survival (PFS)
 Gefitinib $161,781.47 8.180
 Erlotinib $218,411.28 $56,629.81 6.701 −1.48 Dominated
 Afatinib $347,853.28 $129,442.00 9.457 1.28 $101,363.54
Overall Survival (OS)
 Gefitinib $157,891.46 27.098
 Erlotinib $207,416.43 $49,524.98 21.774 −5.32 Dominated
 Afatinib $347,423.61 $140,007.18 37.095 10.00 $14,004.90